Genelux (GNLX) EBITDA (2022 - 2026)

Genelux has reported EBITDA for 5 years, with the latest figure at -$9.2 million in Q1 2026.

• On a quarterly basis, EBITDA fell 17.34% year-over-year to -$9.2 million in Q1 2026; TTM through Mar 2026 was -$34.6 million, a 10.1% decrease from a year earlier, with the FY2025 full-year figure at -$33.2 million, down 4.79% from the prior year.
• EBITDA was -$9.2 million for Q1 2026 at Genelux, up from -$9.4 million in the prior quarter.
• The five-year high for EBITDA was $6.3 million in Q3 2022, with the low at -$9.7 million in Q4 2024.
• Average EBITDA over 5 years is -$6.3 million, with a median of -$7.0 million recorded in 2023.
• The sharpest annual moves came in 2023 and 2025: EBITDA sank 183.65% in 2023, then climbed 3.68% in 2025.
• Over 5 years, EBITDA stood at -$3.1 million in 2022, then tumbled by 126.28% to -$7.0 million in 2023, then plunged by 39.24% to -$9.7 million in 2024, then increased by 3.45% to -$9.4 million in 2025, then grew by 2.56% to -$9.2 million in 2026.
• The last three EBITDA figures came in at -$9.2 million (Q1 2026), -$9.4 million (Q4 2025), and -$8.2 million (Q3 2025), per Business Quant data.